Author

Xiang Guo 1

1 Pfizer Inc,Collegeville,United States

ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS

Geert D’Haens, Alessandro Armuzzi, Chinyu Su, Xiang Guo, Irene Modesto, Rajiv Mundayat, David P. Hudesman, Michael Chiorean

CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Daniel C. Baumgart, Chinyu Su, Kenneth Kwok, Jami A. Kinnucan, Xiang Guo, Susan B. Connelly, Edward V. Loftus Jr., Krisztina B. Gecse, Alessandro Armuzzi

EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS

Julian Panés, Jean-Frederic Colombel, Severine Vermeire, Marla C. Dubinsky, Ala I. Sharara, Nervin Lawendy, Wenjin Wang, Leonardo Salese, Chinyu Su, Irene Modesto, Xiang Guo, Edward V. Loftus Jr.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

Julian Panés, Bruce E. Sands, Remo Panaccione, Nervin Lawendy, nicole kulisek, Xiang Guo, Rajiv Mundayat, Chinyu Su, Geert R. D'Haens, William J. Sandborn, Siew C. Ng

Item 1 - 4 / 4
1